Eesti - eesti - Ravimiamet

viatris limited - tiotroopium - inhalatsioonipulber kõvakapslis - 18mcg 60tk; 18mcg 30tk

Eesti - eesti - Ravimiamet

viatris limited - lamivudiin+abakaviir - õhukese polümeerikattega tablett - 300mg+600mg 30tk; 300mg+600mg 90tk

Eesti - eesti - Ravimiamet

viatris limited - erlotiniib - õhukese polümeerikattega tablett - 100mg 30tk

Eesti - eesti - Ravimiamet

viatris limited - erlotiniib - õhukese polümeerikattega tablett - 150mg 30tk

Eesti - eesti - Ravimiamet

viatris limited - dasatiniib - õhukese polümeerikattega tablett - 50mg 56tk

Eesti - eesti - Ravimiamet

viatris limited - tikagreloor - õhukese polümeerikattega tablett - 90mg 100tk; 90mg 60tk; 90mg 30tk; 90mg 168tk; 90mg 180tk

Eesti - eesti - Ravimiamet

viatris limited - apiksabaan - õhukese polümeerikattega tablett - 2,5mg 168tk; 2,5mg 120tk; 2,5mg 1000tk; 2,5mg 56tk; 2,5mg 100tk; 2,5mg 200tk; 2,5mg 20tk; 2,5mg 10tk

Eesti - eesti - Ravimiamet

viatris limited - apiksabaan - õhukese polümeerikattega tablett - 5mg 120tk; 5mg 200tk; 5mg 28tk; 5mg 180tk; 5mg 100tk; 5mg 1000tk; 5mg 20tk; 5mg 56tk

Eesti - eesti - Ravimiamet

viatris limited - dabigatraaneteksilaat - kõvakapsel - 110mg 180tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

mylan ireland limited - rivaroksabaan - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antitrombootilised ained - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.